COVID-19 associated Mucormycosis among ICU patients: risk factors, control, and challenges.

COVID-19 associated Mucormycosis among ICU patients: risk factors, control, and challenges.

Publication date: Sep 22, 2023

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic is still difficult to be controlled. The spread of this virus and the emergence of new variants are considered a great challenge worldwide. Disturbance in infection control guidelines implementation, use of steroids, antibiotics, hospital crowdedness, and repeated use of oxygen masks during the management of critically ill COVID-19 patients lead to an increase in the rate of opportunistic infections. So, patients need to fight both the virus with its different variants and opportunistic pathogens including bacteria and fungi especially patients with diabetes mellitus, malignancy, or those who undergo hemodialysis and receive deferoxamine. During the pandemic, many cases of Mucormycosis associated with COVID-19 infection were observed in many countries. In this review, we discuss risk factors that increase the chance of infection by opportunistic pathogens, especially fungal pathogens, recent challenges, and control measures.

Concepts Keywords
Coronavirus Control measures
Diabetes Mucormycosis
Fungi Opportunistic pathogens
Hemodialysis Risk factors
Severe SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Mucormycosis
disease MESH infection
drug DRUGBANK Oxygen
disease MESH critically ill
disease MESH opportunistic infections
disease VO Bacteria
disease VO Fungi
disease MESH diabetes mellitus
disease MESH malignancy
drug DRUGBANK Deferoxamine

Original Article

(Visited 1 times, 1 visits today)